ClinicalTrials.gg

Myocardial Ischemia clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,123 studies for Myocardial Ischemia across more than 10 countries. 177 are recruiting or about to start. 421 of them are mainly about Myocardial Ischemia (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 22 narrower conditions too, such as Coronary Artery Disease: 11,028 studies, 1,980 open.

ClinicalTrials.gov finds 11,061 studies for Myocardial Ischemia. How that becomes 1,121 here

This page counts the studies the registry files under Myocardial Ischemia, and those it files under no condition that list Myocardial Ischemiathemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 11,061Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −9,484Filed under a narrower condition, counted on its own pageCoronary Artery Disease 4,362 · Myocardial Infarction 1,531 · Acute Coronary Syndrome 1,026 · Coronary Disease 958 · ST Elevation Myocardial Infarction 522 · Shock, Cardiogenic 234 · 16 more
  3. −5List Myocardial Ischemia as a condition, but the registry did not file them under itMost often written as “Silent Myocardial Ischemia” (2), “Chronic Myocardial Ischemia” (1), and “Perioperative Myocardial Ischemia” (1). The registry filed them under other conditions only, most often Diabetes Mellitus, Type 2 (2) and Ventricular Dysfunction, Left (1).
  4. −451Match it another way46 name it in the title, 3 in a keyword, and 402 by a synonym or other text the search reads.
  5. 1,121The count on this page26 of them list Myocardial Ischemia in their own words; the registry filed them under no condition.

Status

Completed
637
Status unknown
168
Recruiting
135
Terminated
63
Active, not recruiting
49
Not yet recruiting
29

Phase

Phase 3
137
Phase 2
112
Phase 4
89
Phase 1
45
Early Phase 1
9

Where

United States
218
Denmark
95
Italy
87
China
81
Spain
76
Canada
64

Who develops what

Add Myocardial Ischemia to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
TenecteplaseRecent, limited
Evidence
  • NCT05601999 · ao generium · Phase 3 · comparator · “Metalyse” · registered Oct 2022
Boehringer Ingelheim50% of its industry studiesEU: Boehringer Ingelheim (EMA 2001)11 study
AspirinEarlier onlyPhase 4 trial recorded
Evidence
  • NCT00684203 · Merck & Co., Inc · Phase 2 · background · “Aspirin” · registered May 2008
  • NCT00557921 · Cogentus Pharmaceuticals · Phase 3 · comparator · “Plavix (clopidogrel 75 mg) and aspirin” · registered Nov 2007
Bayer25% of its industry studies00 studies
ClopidogrelEarlier only
Evidence
  • NCT00684203 · Merck & Co., Inc · Phase 2 · background · “Clopidogrel” · registered May 2008
  • NCT00557921 · Cogentus Pharmaceuticals · Phase 3 · comparator · “Plavix (clopidogrel 75 mg) and aspirin” · registered Nov 2007
Sanofi35% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 11 generics authorized00 studies

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Myocardial Ischemia studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here NSAIDs 2 open · P2Y12 inhibitors 1 open · Beta blockers 1 open · Statins 8 · ACE inhibitors 6

Coming up

52studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 135 Myocardial Ischemia studies recruiting now, 92 (68%) set no upper age limit and 6 (4%) stop at 75 or younger. 14 (10%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 20 (15%) take healthy volunteers.

Recruiting studies that take each age, of 135
AgeWomenMen
1012 (9%)12 (9%)
18108 (80%)108 (80%)
30121 (90%)121 (90%)
40124 (92%)124 (92%)
50129 (96%)129 (96%)
65132 (98%)132 (98%)
75131 (97%)131 (97%)
85114 (84%)114 (84%)

Across all 1,123 studies, recruiting or not: 14% stop at 75 or younger and 3% at 65; 9% take children; 2% are for women only and 3% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Myocardial Ischemia studies take

Of 21 phase 4 interventional studies under Myocardial Ischemia, half reached primary completion within 48 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 229 mo19–47 · 16 studies——
Phase 340 mo21–51 · 17 studies——
Phase 448 mo37–59 · 21 studies——
Interventional, no phase34 mo15–58 · 192 studies34 mo14–58 · 37 studies33 mo15–56 · 155 studies
Observational40 mo21–90 · 204 studies27 mo16–40 · 39 studies51 mo23–127 · 165 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,123. Browse all 1,123 → or search them.